Asarina Pharma AB

Equities

ASAP

SE0011641794

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 06:47:54 2024-04-30 am EDT			5-day change	1st Jan Change
0.968 ^SEK	-1.22%		+7.56%	+10.00%

Feb. 27	Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Asarina Pharma AB Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2022

February 27, 2023 at 02:30 am EST

Asarina Pharma AB (publ) reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was SEK 13.28 million compared to SEK 31.66 million a year ago. Basic loss per share from continuing operations was SEK 0.71 compared to SEK 1.69 a year ago.

Latest news about Asarina Pharma AB

Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Asarina Pharma AB Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-23	CI
Asarina Pharma's Positive Phase IIa Tourette Syndrome Results to Be Presented At Ticcon, the Virtual National Conference of the Tourette Association of America	23-05-05	CI
Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Asarina Pharma Completes Recruitment For Clinical Study On Tourette Syndrome	22-10-14	MT
Asarina Pharma Completes Recruitment of Patients to its Phase IIa Clinical Study in Tourette Syndrome	22-10-14	CI
Asarina Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-25	CI
Asarina Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-25	CI
Asarina Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-24	CI
Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-24	CI
Asarina Pharma AB Announces That `First Patient First Visit' Has Taken Place in Its Phase Ii A Clinical Study in Tourette Syndrome At Bispebjerg University Hospital, Copenhagen	22-02-16	CI
Asarina Pharma Receives Final Approval for Phase IIa Tourette Study	21-12-22	CI
Asarina Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-25	CI
Pmdd Phase Iib Study, Including Post-Hoc Analysis Showing ‘Significant Treatment Effect	21-09-28	CI
Asarina Pharma Announces Administrative Backlog At Public Authority Causes Short-Term Delay in Tourette Study	21-09-16	CI
Asarina Pharma AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-19	CI
Asarina Pharma Reports Topline Results in Phase IIa Menstrual Migraine Study	21-06-23	CI
The US Patent and Trademark Office Grants Asarina Pharma's Patent for Sepranolone for the Treatment of Tourette, Obsessive-Compulsive Disorder and Pathological Gambling	21-06-08	CI
Asarina Pharma AB Receives Approval of CTA for Phase IIa Tourette Study	21-05-19	CI
Asarina Pharma AB Publ Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-18	CI
Asarina Pharma AB Confirms New Preclinical Study That Sepranolone Suppresses Tics in Tourette Syndrome	21-02-11	CI
Asarina Pharma AB Publ Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-25	CI
Asarina Pharma AB Reaches Full Patient Enrolment in Its Phase Iia Menstrual Migraine (Mm) Study	20-09-30	CI
Asarina Pharma AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-19	CI
Asarina Pharma AB Publ Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-26	CI

Chart Asarina Pharma AB

Duration

Period

More charts

Company Profile

Asarina Pharma AB (publ), formerly Umecrine Mood, is a Sweden-based biotech company within area of womenâs health. The Companyâs main product is Sepranolone, a treatment for Premenstrual dysphoric disorder (PDD), a form of Premenstrual syndrome (PMS). Sepranolone (UC1010) is an endogenous compound occurring naturally in the brain. Sepranolone inhibits the effects of allopregnanolone, the steroid that causes PMDD. Moreover, Sepranolone is applicable for treatment of menstrual migraine. Additionally to clinical trials with sepranolone, the Company develops a sepranolone analog that is a similar substance, which allows for alternative administration. The Company conducts trials in Europe. The Companyâs main shareholders are Kurma Biofund and The Foundation for Baltic and East European Studies.

Sector

Biotechnology & Medical Research

Calendar

2024-05-20 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ASARINA PHARMA AB	+10.00%	2M
VERTEX PHARMACEUTICALS INCORPORATED	-3.46%	102B
REGENERON PHARMACEUTICALS, INC.	+1.41%	96.09B
ARGENX SE	+2.13%	22.28B
BIONTECH SE	-15.84%	21.4B
GENMAB A/S	-9.21%	18.14B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-14.65%	16.09B
NEUROCRINE BIOSCIENCES, INC.	+4.39%	13.83B
SAREPTA THERAPEUTICS, INC.	+31.35%	11.97B

Bio Therapeutic Drugs